Astellas And Effector Cell Institute To Jointly Develop Autoimmune Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has signed a licensing deal with Tokyo-based Effector Cell Institute to develop a new drug based on the novel target protein FROUNT in the area of autoimmune disorders, such as transplant rejection and rheumatoid arthritis. Under the license, Effector will receive an up-front payment and research fees, as well as development milestones related to the compound. (Click for more-Japanese language
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.